Evidence map›Paper›PMID 32724273›Full record

ArticleActa clinica Croatica2020

THE FREQUENCY OF FOLLICLE-STIMULATING HORMONE RECEPTOR 2039A>G GENE POLYMORPHISM AND THE RISK OF MALE INFERTILITY IN ALBANIAN POPULATION.

Elezaj Shkelzen, Frane Paić, Feodora Stipoljev, Zafer Gashi, Afrim Zeqiraj, Albert Lila, Tamara Nikuševa Martić

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Elezaj Shkelzen1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
Frane Paić1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
Feodora Stipoljev1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
Zafer Gashi1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
Afrim Zeqiraj1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
Albert Lila1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
Tamara Nikuševa Martić1University of Zagreb, School of Medicine, Zagreb, Croatia; 2Laboratory for Epigenetics and Molecular Medicine, Department of Biology and Medical Genetics, School of Medicine, Zagreb, Croatia; 3Laboratory for Cytogenetics, Department of Gynecology and Obstetrics, Sveti Duh University Hospital, Zagreb, Croatia; 4Department of Biochemistry, FAMA College, Republic of Kosovo; 5Department of Gynecology, Regional Hospital, Gjakova, Republic of Kosovo.
University of Zagreb · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to determine the prevalence of allele and genotype variants of the follicle-stimulating hormone receptor (FSHR) gene polymorphic region at position Asn680Ser in the Albanian male population and associate them with the clinical parameters of infertility. The study included 114 infertile men (mean age 35.04±5.85 years) stratified according to the level of spermatogenetic impairment (oligoasthenozoospermia, asthenozoospermia and normospermia) and 112 fertile men (mean age 36.44±7.05 years) with normal semen parameters. Genotyping of the FSHR gene at position 680 was performed by TaqMan genotyping assay. All the participants underwent semen analysis, and serum reproductive hormones (FSH, luteinizing hormone, prolactin and testosterone) were also measured. The FSHR Asn680Ser genotype frequencies were as follows: Asn/Ser 42%, Ser/Ser 33.9% and Asn/Asn 24.1% in the control group, and Asn/Ser 56.1%, Ser/Ser 22.8% and Asn/Asn 21.1% in the whole group of infertile men (χ

Indexed as

Infertility, MaleReceptors, FSHAdultCase-Control StudiesFollicle Stimulating HormoneHumansMalePolymorphism, GeneticSperm MotilityFollicle Stimulating HormoneFSHR protein, humanReceptors, FSHCase-control studiesInfertility, maleProlactinReceptors, FSHTestosterone

Identifiers

PMID32724273
PMCPMC7382881
OpenAlexW3046310465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.